Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B15 / EV-304 perioperative enfortumab vedotin plus pembrolizumab vs gemcitabine/cisplatin in muscle-invasive bladder cancer
jRCT2041210011Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and enfortumab vedotin in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Merck & Co. Primary endpoints: Pathological Complete Response (pCR) Rate and Event-free Survival (EFS. Started Jun 2021; status: active, not recruiting.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2041210011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210011.